- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06676319
Estudo de Lunsekimig (SAR443765) comparado com placebo em adultos com asma de alto risco (AIRLYMPUS)
Um estudo randomizado, de fase 2, duplo-cego, controlado por placebo, de grupo paralelo, de 2 braços para investigar a eficácia, segurança e tolerabilidade do Lunsekimig subcutâneo (SAR443765) em participantes adultos com asma de alto risco que não são atualmente elegíveis para tratamento biológico
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.
Study details include:
- The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study.
- The investigational treatment duration will be up to approximately 52 weeks.
- The number of visits will be 18.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Ahrensburg, Alemanha, 22926
- Investigational Site Number : 2760006
-
Bendorf, Alemanha, 56170
- Investigational Site Number : 2760002
-
Berlin, Alemanha, 12159
- Investigational Site Number : 2760007
-
Frankfurt, Alemanha, 60596
- Investigational Site Number : 2760004
-
Frankfurt, Alemanha, 60596
- Investigational Site Number : 2760008
-
Frankfurt am Main, Alemanha, 60389
- Investigational Site Number : 2760003
-
Leipzig, Alemanha, 04347
- Investigational Site Number : 2760001
-
Mainz, Alemanha, 55128
- Investigational Site Number : 2760005
-
-
-
-
-
Buenos Aires, Argentina, 1121
- Investigational Site Number : 0320005
-
Buenos Aires, Argentina, 1425
- Investigational Site Number : 0320001
-
Buenos Aires, Argentina, 1425
- Investigational Site Number : 0320004
-
Buenos Aires, Argentina, 1122
- Investigational Site Number : 0320012
-
Buenos Aires, Argentina, 1414
- Investigational Site Number : 0320002
-
Corrientes, Argentina, 3400
- Investigational Site Number : 0320008
-
La Plata, Buenos Aires, Argentina, B1904CUL
- Investigational Site Number : 0320011
-
Mendoza, Argentina, 5500
- Investigational Site Number : 0320015
-
Mendoza, Argentina, 5500
- Investigational Site Number : 0320014
-
Santa Fe, Argentina, 3000
- Investigational Site Number : 0320009
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentina, 1886
- Investigational Site Number : 0320007
-
Lobos, Buenos Aires, Argentina, 7240
- Investigational Site Number : 0320013
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Investigational Site Number : 0320006
-
Rosario, Santa Fe Province, Argentina, 2000
- Investigational Site Number : 0320010
-
Rosario, Santa Fe Province, Argentina, 2000
- Investigational Site Number : 0320016
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Investigational Site Number : 0320003
-
-
-
-
-
São Paulo, Brasil, 05403-000
- Incor - Instituto do Coracao- Site Number : 0760004
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40060-330
- Associacao Proar- Site Number : 0760002
-
-
Goiás
-
Goiânia, Goiás, Brasil, 74605-020
- Universidade Federal de Goias- Site Number : 0760011
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80060-900
- Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760006
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
-
Porto Alegre, Rio Grande do Sul, Brasil, 91010-006
- WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760003
-
-
-
-
-
Liège, Bélgica, 4000
- Investigational Site Number : 0560003
-
Mechelen, Bélgica, 2800
- Investigational Site Number : 0560002
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Canadá, V1Y 4N7
- Investigational Site Number : 1240011
-
West Vancouver, British Columbia, Canadá, V7T 2Z3
- Investigational Site Number : 1240012
-
-
Ontario
-
Ajax, Ontario, Canadá, L1S 2J5
- Investigational Site Number : 1240013
-
Guelph, Ontario, Canadá, N1h 6j2
- Investigational Site Number : 1240003
-
Stoney Creek, Ontario, Canadá, L8G 2V6
- Investigational Site Number : 1240006
-
Toronto, Ontario, Canadá, M4G 3E8
- Investigational Site Number : 1240008
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 3E4
- Investigational Site Number : 1240014
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- Investigational Site Number : 1240002
-
-
-
-
Biobio
-
Concepción, Biobio, Chile, 4070094
- Investigational Site Number : 1520008
-
-
Maule Region
-
Talca, Maule Region, Chile, 3465584
- Investigational Site Number : 1520002
-
-
Reg Metropolitana de Santiago
-
Lo Barnechea, Reg Metropolitana de Santiago, Chile, 7691236
- Investigational Site Number : 1520009
-
Recoleta, Reg Metropolitana de Santiago, Chile, 8420000
- Investigational Site Number : 1520010
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500692
- Investigational Site Number : 1520001
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500698
- Investigational Site Number : 1520003
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500587
- Investigational Site Number : 1520006
-
-
Valparaiso
-
Quillota, Valparaiso, Chile, 2260877
- Investigational Site Number : 1520005
-
Viña del Mar, Valparaiso, Chile, 2540364
- Investigational Site Number : 1520007
-
Viña del Mar, Valparaiso, Chile, 2531172
- Investigational Site Number : 1520004
-
-
-
-
-
Beijing, China, 100029
- Investigational Site Number : 1560027
-
Changchun, China, 130021
- Investigational Site Number : 1560005
-
Chengde, China, 067020
- Investigational Site Number : 1560021
-
Chengdu, China, 611130
- Investigational Site Number : 1560039
-
Foshan, China, 528399
- Investigational Site Number : 1560028
-
Guangzhou, China, 510000
- Investigational Site Number : 1560010
-
Guangzhou, China, 510180
- Investigational Site Number : 1560033
-
Guiyang, China, 550002
- Investigational Site Number : 1560037
-
Hangzhou, China, 310005
- Investigational Site Number : 1560042
-
Hebei, China, 050051
- Investigational Site Number : 1560009
-
Hohhot, China, 010050
- Investigational Site Number : 1560006
-
Hohhot, China, 010070
- Investigational Site Number : 1560007
-
Huizhou, China, 516001
- Investigational Site Number : 1560029
-
Huizhou, China, 516002
- Investigational Site Number : 1560011
-
Jiazhuang, China, 050000
- Investigational Site Number : 1560025
-
Jinan, China, 250001
- Investigational Site Number : 1560034
-
Jinan, China, 250014
- Investigational Site Number : 1560038
-
Lanzhou, China, 730000
- Investigational Site Number : 1560030
-
Luoyang, China, 471003
- Investigational Site Number : 1560018
-
Nanchang, China, 330006
- Investigational Site Number : 1560003
-
Ningbo, China, 315010
- Investigational Site Number : 1560014
-
Shanghai, China, 200080
- Investigational Site Number : 1560001
-
Shanghai, China, 200433
- Investigational Site Number : 1560043
-
Shenyang, China, 110004
- Investigational Site Number : 1560016
-
Suzhou, China, 215002
- Investigational Site Number : 1560019
-
Taiyuan, China, 030001
- Investigational Site Number : 1560017
-
Taiyuan, China, 030032
- Investigational Site Number : 1560035
-
Tianjin, China, 300211
- Investigational Site Number : 1560013
-
Wuhan, China, 430030
- Investigational Site Number : 1560022
-
Xi'an, China, 710004
- Investigational Site Number : 1560036
-
Xi'an, China, 710061
- Investigational Site Number : 1560032
-
Xianyang, China, 712000
- Investigational Site Number : 1560044
-
Xuzhou, China, 221006
- Investigational Site Number : 1560012
-
Yangzhou, China, 225000
- Investigational Site Number : 1560047
-
Zhengzhou, China, 450003
- Investigational Site Number : 1560023
-
Zhengzhou, China, 450007
- Investigational Site Number : 1560026
-
Zigong, China, 643000
- Investigational Site Number : 1560045
-
-
-
-
-
Hvidovre, Dinamarca, 2650
- Investigational Site Number : 2080001
-
Vejle, Dinamarca, 7100
- Investigational Site Number : 2080002
-
-
-
-
-
Girona, Espanha, 17005
- Investigational Site Number : 7240016
-
Madrid, Espanha, 28041
- Investigational Site Number : 7240002
-
Madrid, Espanha, 28003
- Investigational Site Number : 7240013
-
Madrid, Espanha, 28007
- Investigational Site Number : 7240008
-
Madrid, Espanha, 28010
- Investigational Site Number : 7240011
-
Málaga, Espanha, 29010
- Investigational Site Number : 7240006
-
Palma, Espanha, 07120
- Investigational Site Number : 7240001
-
Seville, Espanha, 41012
- Investigational Site Number : 7240014
-
-
A Coruña [La Coruña]
-
Santiago de Compostela, A Coruña [La Coruña], Espanha, 15702
- Investigational Site Number : 7240005
-
-
Barcelona [Barcelona]
-
Badalona, Barcelona [Barcelona], Espanha, 08916
- Investigational Site Number : 7240010
-
-
Cantabria
-
Santander, Cantabria, Espanha, 39008
- Investigational Site Number : 7240017
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Espanha, 08017
- Investigational Site Number : 7240009
-
Barcelona, Catalunya [Cataluña], Espanha, 08035
- Investigational Site Number : 7240015
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espanha, 28046
- Investigational Site Number : 7240007
-
-
Málaga
-
Benalmádena, Málaga, Espanha, 29631
- Investigational Site Number : 7240018
-
-
-
-
Alabama
-
Saraland, Alabama, Estados Unidos, 36571
- The Center for Clinical Trials - Saraland- Site Number : 8400096
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Chandler Clinical Research Trials- Site Number : 8400075
-
Sun City, Arizona, Estados Unidos, 85351
- Epic Medical Research - Sun City- Site Number : 8400052
-
Tucson, Arizona, Estados Unidos, 85712
- Tucson Clinical Research Institute- Site Number : 8400085
-
-
California
-
Long Beach, California, Estados Unidos, 90815
- Ark Clinical Research- Site Number : 8400097
-
Los Angeles, California, Estados Unidos, 90017
- Downtown L.A. Research Center- Site Number : 8400080
-
North Hollywood, California, Estados Unidos, 91606
- Carbon Health - North Hollywood - NoHo West- Site Number : 8400061
-
San Mateo, California, Estados Unidos, 94403
- Carbon Health - San Mateo - Hillsdale Mall- Site Number : 8400062
-
Stanford, California, Estados Unidos, 94305
- Stanford University Medical Center- Site Number : 8400108
-
Torrance, California, Estados Unidos, 90505
- Modena Allergy And Asthma- Site Number : 8400068
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20060
- Howard University Hospital- Site Number : 8400107
-
-
Florida
-
Boynton Beach, Florida, Estados Unidos, 33435
- Helix Biomedics- Site Number : 8400005
-
Cutler Bay, Florida, Estados Unidos, 33157
- Beautiful Minds Clinical Research Center- Site Number : 8400019
-
DeBary, Florida, Estados Unidos, 32713
- Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400082
-
Hollywood, Florida, Estados Unidos, 33024
- Alfa Medical Research- Site Number : 8400071
-
Inverness, Florida, Estados Unidos, 34453
- Royal Clinical Trials - Inverness- Site Number : 8400067
-
Lady Lake, Florida, Estados Unidos, 32159
- Premier Medical Associates- Site Number : 8400077
-
Margate, Florida, Estados Unidos, 33063
- D&H Pompano Research Center- Site Number : 8400072
-
Miami, Florida, Estados Unidos, 33173
- Research Institute of South Florida- Site Number : 8400023
-
Miami, Florida, Estados Unidos, 33186
- Innovations Biotech- Site Number : 8400044
-
Pembroke Pines, Florida, Estados Unidos, 33025
- Tellabio International Research Services- Site Number : 8400083
-
Pensacola, Florida, Estados Unidos, 32503
- Avanza Medical Research Center- Site Number : 8400056
-
Saint Cloud, Florida, Estados Unidos, 34769
- Ilumina Medical Research- Site Number : 8400095
-
-
Georgia
-
Cordele, Georgia, Estados Unidos, 31015
- Private Practice - Dr. David Kavtaradze- Site Number : 8400081
-
Riverdale, Georgia, Estados Unidos, 30274
- EmVenio Research - Riverdale- Site Number : 8400109
-
-
Illinois
-
Champaign, Illinois, Estados Unidos, 61820
- Christie Clinic in Champaign on University- Site Number : 8400003
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Medical Center- Site Number : 8400105
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20854
- Velocity Clinical Research - Rockville (formerly Meridian Clinical Research)- Site Number : 8400036
-
Silver Spring, Maryland, Estados Unidos, 20901
- Javara - Privia Medical Group - Silver Spring Lockwood- Site Number : 8400042
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400014
-
Clarkston, Michigan, Estados Unidos, 48346
- Clarkston Medical Group- Site Number : 8400054
-
-
Minnesota
-
Mankato, Minnesota, Estados Unidos, 56001
- Javara - Mankato Clinic- Site Number : 8400001
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester - Minnesota- Site Number : 8400057
-
-
Missouri
-
Hannibal, Missouri, Estados Unidos, 63401
- Hannibal Regional Healthcare System- Site Number : 8400078
-
-
New York
-
New York, New York, Estados Unidos, 10011
- Icahn School of Medicine at Mount Sinai (ISMMS) - Mount Sinai Doctors- Site Number : 8400069
-
New York, New York, Estados Unidos, 10016
- Pioneer Clinical Research - New York- Site Number : 8400092
-
-
North Carolina
-
Statesville, North Carolina, Estados Unidos, 28625
- Piedmont Healthcare - Family Medicine- Site Number : 8400064
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic - Cleveland- Site Number : 8400106
-
Toledo, Ohio, Estados Unidos, 43617
- Asthma & Allergy Center - Toledo- Site Number : 8400020
-
-
Oklahoma
-
Edmond, Oklahoma, Estados Unidos, 73034
- OK Clinical Research- Site Number : 8400060
-
-
Pennsylvania
-
DuBois, Pennsylvania, Estados Unidos, 15801
- Clinical Research Associates of Central Pennsylvania- Site Number : 8400013
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University Hospital- Site Number : 8400110
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29607
- Allergic Disease and Asthma Center (ADAC)- Site Number : 8400070
-
-
Texas
-
Austin, Texas, Estados Unidos, 78759
- Orion Clinical Research- Site Number : 8400084
-
Boerne, Texas, Estados Unidos, 78006
- South Texas Medical Research Institute - TTS Research- Site Number : 8400015
-
DeSoto, Texas, Estados Unidos, 75115
- Epic Medical Research - De Soto- Site Number : 8400051
-
Houston, Texas, Estados Unidos, 77058
- Axsendo Clinical Research - Houston- Site Number : 8400065
-
McKinney, Texas, Estados Unidos, 75069
- Metroplex Pulmonary and Sleep Center- Site Number : 8400012
-
San Antonio, Texas, Estados Unidos, 78229
- STAAMP Research - San Antonio- Site Number : 8400059
-
San Antonio, Texas, Estados Unidos, 78249
- Bandera Family Health Care - San Antonio- Site Number : 8400049
-
San Marcos, Texas, Estados Unidos, 78666
- Javara - San Marcos - Redwood Road- Site Number : 8400040
-
Sugar Land, Texas, Estados Unidos, 77478
- Simcare Medical Research- Site Number : 8400102
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Children's Wisconsin- Site Number : 8400073
-
-
-
-
-
Amiens, França, 80000
- Investigational Site Number : 2500007
-
Lyon, França, 69004
- Investigational Site Number : 2500004
-
Montpellier, França, 34090
- Investigational Site Number : 2500003
-
Paris, França, 75018
- Investigational Site Number : 2500006
-
Pessac, França, 33604
- Investigational Site Number : 2500005
-
Strasbourg, França, 67000
- Investigational Site Number : 2500001
-
Toulouse, França, 31059
- Investigational Site Number : 2500002
-
-
-
-
-
Debrecen, Hungria, 4032
- Investigational Site Number : 3480006
-
Gödöllő, Hungria, 2100
- Investigational Site Number : 3480002
-
Hajdúnánás, Hungria, 4080
- Investigational Site Number : 3480003
-
Mosonmagyaróvár, Hungria, 9200
- Investigational Site Number : 3480004
-
Pécs, Hungria, 7635
- Investigational Site Number : 3480005
-
Püspökladány, Hungria, 4150
- Investigational Site Number : 3480001
-
-
-
-
-
Haifa, Israel, 3436212
- Investigational Site Number : 3760006
-
Jerusalem, Israel, 9103102
- Investigational Site Number : 3760003
-
Jerusalem, Israel, 9112001
- Investigational Site Number : 3760002
-
Petah Tikva, Israel, 4941492
- Investigational Site Number : 3760005
-
Rehovot, Israel, 7610001
- Investigational Site Number : 3760001
-
Tel Aviv, Israel, 6423906
- Investigational Site Number : 3760004
-
-
-
-
-
Bergamo, Itália, 24127
- Investigational Site Number : 3800007
-
Modena, Itália, 41125
- Investigational Site Number : 3800005
-
Palermo, Itália, 90127
- Investigational Site Number : 3800013
-
Reggio Emilia, Itália, 42100
- Investigational Site Number : 3800011
-
Tradate (Va), Itália, 21049
- Investigational Site Number : 3800012
-
-
Ancona
-
Torette, Ancona, Itália, 60020
- Investigational Site Number : 3800008
-
-
Cagliari
-
Monserrato, Cagliari, Itália, 09042
- Investigational Site Number : 3800006
-
-
Ferrara
-
Cona, Ferrara, Itália, 44124
- Investigational Site Number : 3800001
-
-
Genova
-
Genoa, Genova, Itália, 16132
- Investigational Site Number : 3800009
-
-
Milano
-
Milan, Milano, Itália, 20122
- Investigational Site Number : 3800004
-
Rozzano, Milano, Itália, 20089
- Investigational Site Number : 3800003
-
-
Roma
-
Rome, Roma, Itália, 00168
- Investigational Site Number : 3800010
-
-
-
-
Yamaguchi
-
Ube, Yamaguchi, Japão, 755-8505
- Investigational Site Number : 3920001
-
-
-
-
-
Chęciny, Polônia, 26-060
- Investigational Site Number : 6160004
-
Katowice, Polônia, 40-600
- Investigational Site Number : 6160009
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polônia, 60-693
- Investigational Site Number : 6160001
-
Poznan, Greater Poland Voivodeship, Polônia, 60-309
- Investigational Site Number : 6160005
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polônia, 15-044
- Investigational Site Number : 6160002
-
-
Świętokrzyskie Voivodeship
-
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polônia, 27-400
- Investigational Site Number : 6160003
-
-
-
-
-
Barnsley, Reino Unido, S75 2EP
- Investigational Site Number : 8260005
-
Bradford, Reino Unido, BD9 6DA
- Investigational Site Number : 8260003
-
London, Reino Unido, W1G 8HU
- Investigational Site Number : 8260001
-
-
Hillingdon
-
Ruislip, Hillingdon, Reino Unido, HA4 8NX
- Investigational Site Number : 8260009
-
-
Northamptonshire
-
Corby, Northamptonshire, Reino Unido, NN17 2UN
- Investigational Site Number : 8260007
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Reino Unido, NG7 2UH
- Investigational Site Number : 8260006
-
-
Oxfordshire
-
Oxford, Oxfordshire, Reino Unido, OX3 9DU
- Investigational Site Number : 8260008
-
-
-
-
-
Bucharest, Romênia, 011658
- Investigational Site Number : 6420001
-
Cluj-Napoca, Romênia, 400006
- Investigational Site Number : 6420002
-
-
-
-
-
Lund, Suécia, 221 85
- Investigational Site Number : 7520002
-
-
-
-
-
Hualien City, Taiwan, 970
- Investigational Site Number : 1580002
-
Kaohsiung City, Taiwan, 80756
- Investigational Site Number : 1580005
-
Taichung, Taiwan, 404
- Investigational Site Number : 1580006
-
Taichung, Taiwan, 407
- Investigational Site Number : 1580007
-
Taipei, Taiwan, 100
- Investigational Site Number : 1580004
-
Taipei, Taiwan, 110
- Investigational Site Number : 1580003
-
Taoyuan City, Taiwan, 333
- Investigational Site Number : 1580001
-
-
-
-
-
Kayseri, Turquia (Türkiye), 38039
- Investigational Site Number : 7920003
-
Kirikkale, Turquia (Türkiye), 71100
- Investigational Site Number : 7920002
-
Mersin, Turquia (Türkiye), 33070
- Investigational Site Number : 7920001
-
-
-
-
-
Benoni, África do Sul, 1500
- Investigational Site Number : 7100004
-
Benoni, África do Sul, 1500
- Investigational Site Number : 7100005
-
Cape Town, África do Sul, 7530
- Investigational Site Number : 7100002
-
Durban, África do Sul, 4001
- Investigational Site Number : 7100006
-
Durban, África do Sul, 3630
- Investigational Site Number : 7100003
-
Johannesburg, África do Sul, 1821
- Investigational Site Number : 7100007
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Physician-diagnosed mild-to-moderate asthma for more than 12 months based on GINA guidelines.
- At least 1 asthma exacerbation in the year prior to Screening (Visit 1).
- Pre-BD FEV1 of equal or more than 40% of predicted normal (by Global Lung Function Initiative [GLI] standards) at Screening (Visit 1).
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Other severe lung diseases (eg, chronic obstructive pulmonary disease [COPD]. bronchiectasis, idiopathic pulmonary fibrosis, etc) which may impair lung function.
- Participants who experience a deterioration of asthma that results in emergency treatment or hospitalization, or treatment with systemic steroids within 1 month prior to the Screening (Visit 1) (counting from the date of completion of treatment for asthma exacerbation).
- Participants who have experienced an upper or lower respiratory tract infection within the 4 weeks prior to Screening (Visit 1).
- Known history of, or suspected, significant current immunosuppression, including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
- Evidence of any infection requiring systemic anti-infective treatment within 2 weeks before Screening (Visit 1) or during the screening period. Significant viral infections within 2 weeks before Screening (Visit 1) or during the screening period even if the participant has not received systemic antiviral treatment (eg, influenza receiving only symptomatic treatment).
- Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB (such as close contact with individuals with active TB), or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1).
- Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure, and pulmonary disease.
NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Lunsekimig
Participants will receive lunsekimig (SC injection) every 4 weeks |
Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection
Outros nomes:
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration:Oral Inhalation Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation Pharmaceutical form: Aerosol for inhalation; Route of administration: Oral Inhalation |
|
Comparador de Placebo: Placebo
Participants will receive placebo (SC injection) every 4 weeks |
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration:Oral Inhalation Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation Pharmaceutical form: Aerosol for inhalation; Route of administration: Oral Inhalation Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Annualized rate of asthma exacerbation events
Prazo: From baseline up to 52 weeks
|
Asthma exacerbation event defined as: worsening of asthma requiring the use of systemic corticosteroids for ≥3 days; or hospitalization or emergency room visit due to asthma and requiring the use of systemic corticosteroids or death due to asthma |
From baseline up to 52 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Alteração da linha de base no volume expiratório forçado pré-broncodilatador (BD) em 1 segundo (FEV1)
Prazo: Da linha de base até a semana 52
|
Da linha de base até a semana 52
|
|
|
Alteração da linha de base no nível de FeNO
Prazo: Da linha de base até a semana 52
|
Da linha de base até a semana 52
|
|
|
Taxa anualizada de exacerbações de asma que requerem hospitalização, atendimento de emergência ou atendimento de urgência
Prazo: Da linha de base até a semana 52
|
Da linha de base até a semana 52
|
|
|
Exposição total à dose sistêmica de corticosteroide
Prazo: Da linha de base até a semana 52
|
Da linha de base até a semana 52
|
|
|
Alteração da linha de base nas pontuações do Questionário Padronizado de Qualidade de Vida em Asma (AQLQ{S})
Prazo: Da linha de base até a semana 52
|
Da linha de base até a semana 52
|
|
|
Alteração da linha de base na pontuação diária de manhã e noite do Diário de Sintomas Diurnos de Asma (ADSD)
Prazo: Da linha de base até a semana 52
|
Da linha de base até a semana 52
|
|
|
Concentrações séricas de lunsekimig
Prazo: Da linha de base até a semana 56
|
Da linha de base até a semana 56
|
|
|
Incidência e título de anticorpos antidrogas (ADA) contra lunsekimig
Prazo: Da linha de base até a semana 56
|
Da linha de base até a semana 56
|
|
|
Incidência de participantes com eventos adversos emergentes do tratamento (TEAE), incluindo reações locais, eventos adversos de interesse especial (EAIE), eventos adversos graves (EAG)
Prazo: Da linha de base até a semana 56
|
Da linha de base até a semana 56
|
|
|
Change from baseline in Asthma Control Questionnaire5 (ACQ-5) score
Prazo: From baseline to week 52
|
The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control. |
From baseline to week 52
|
|
Annualized rate of loss of asthma control events (LOAC) events
Prazo: From baseline to week 52
|
Annualized rate of LOAC events defined by 1 or more of the following criteria:
|
From baseline to week 52
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Doenças Respiratórias
- Doenças pulmonares
- Doenças brônquicas
- Doenças Pulmonares Obstrutivas
- Hipersensibilidade Respiratória
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Asma
- Produtos químicos orgânicos
- Preparações farmacêuticas
- Compostos policíclicos
- Aminas
- Pregnas
- Esteróides
- Compostos de anel fundido
- Álcoons
- Álcoois amino
- Androstadienes
- Androstenes
- Androstanos
- Etanolaminas
- Feneetilaminas
- Etilaminas
- Greattenenes
- Gestenos
- Combinações de drogas
- Fumarato de formoterol
- Salmeterol xinafoato
- Fluticasona
- Combinação de Medicamentos Fluticasona-Salmeterol
- Combinação de medicamentos budesonida e fumarato de formoterol
- Albuterol
- Budesonida
Outros números de identificação do estudo
- ACT18301
- 2024-513959-33 (Identificador de registro: CTIS)
- U1111-1301-3938 (Identificador de registro: ICTRP)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .